TAKEDA PHARMACEUTICAL COMPANY LIMITED 1 Revised: October 2009 (12th version) Standard Commodity Classification No. of Japan 873969 - Improving agent for postprandial hyperglycemia – BASEN® Tablets 0.2 BASEN® Tablets 0.3 Prescription drug Caution - Use only pursuant to the prescription of a physician etc. CONTRAINDICATIONS (BASEN® Tablets are contra-indicated in the following patients.) (1) Patients with severe ketosis, or in a state of diabetic coma or pre-coma [Since it becomes essential to quickly rectify hyperglycemia with administration of intrave-nous fluid or insulin, the use of BASEN ® Tablets is not suitable.] (2) Patients with severe infections, before or after operation, or with serious trauma [It is desirable to control plasma glucose with the injection of insulin. Therefore, ad-ministration of this drug is not appropriate.] (3) Patients with a history of hypersensitivity to any of the ingredients of this drug DESCRIPTION This drug is Voglibose tablets (Japanese Pharmacopoeia). BASEN® Tablets 0.2 BASEN® Tablets 0.3Active ingredient per tablet Voglibose 0.2 mg Voglibose 0.3 mg Dosage form Plain-scored tablets Plain tablets Color of tablet White to yellowish - white Identification Code 351 352 Shape Upper Lower Side Upper Lower SideDiameter (mm) 7.1 8.1 Thickness (mm) 2.6 3.1 Inactive ingredients: Corn Starch, Hydroxypropylcellulose, Magnesium Stearate, Lactose INDICATIONS ○ Improvement of postprandial hyperglycemia in diabetes mel-litus (However, BASEN® Tablets should be used only when sufficient effect has not been obtained in patients already un-dergoing dietary treatment and/or exercise therapy, or when sufficient effect has not been obtained in patients ...
